- ... months) MMSE (12 months) – sensitivity analysis excluding rofecoxib ADCS-ADL (12 months) ADCS-ADL (12 months) – sensitivity analysis excluding rofecoxib ADCS-ADL, ...
- ... to Moderate NR ADAS-cog (11-item) NR ADCS-ADL NR CDR, Sum of Boxes NR Omega-3 ... Mild to Moderate AD MMSE ADAS-Cog NR ADCS-ADL NR CDR, Sum of Boxes NR TOTAL 10 ...
- ... 54 Cognitive Tests ADAS-Cog MMSE SIB Function ADCS-ADL DAD IDDD Global Impression of Change GDS CGIC ... Placebo 24 weeks Cognitive Tests ADAS-Cog Function ADCS-ADL Harms SAEs Withdrawal due to AE All-cause ...
- ... Galantamine Auchus, 2007 204 Fair Dem ADL/IADL (ADCS-ADL, 0–78, ↑) IG1 6 48.3 (17.2) ‡ ... Brodaty, 2005 205 Fair-Good Dem ADL/IADL (ADCS-ADL, 0–78, ↑) IG1 3 52.0 (0.90) ...
- ... inhibitor Simvastatin Sano, 2011 239 Fair Dem ADL (ADCS-ADL, 0–27, ↓) IG1 3 67.2 (10.0) ... NS HMG-CoA reductase inhibitor Simvastatin Dem ADL (ADCS-ADL, 0–27, ↓) IG1 6 67.2 (10.0) ...
- ... s Disease Cooperative Study - Activities of Daily Living [ADCS-ADL] scale). The ADCS-ADL is a multi-item instrument used to assess ... or the need for assistance. Scores on the ADCS-ADL range from 0 to 78, with higher scores ...
- ... NS Orrell, 2014 * 281 Good Dem ADL/IADL (ADCS-ADL, 0–78, ↑) IG1 3 42.7 (17.2) ... 08, 5.20), 0.04 Dem ADL/IADL (ADCS-ADL, 0–78, ↑) IG1 6 42.7 (17.2) ... NS Hoffmann, 2016 * 304 Good Dem ADL/IADL (ADCS-ADL, 0–78, ↑) IG1 4 64.8 (8.8) ...
- ... verbal fluency (VFT) and activities of daily living (ADCS-ADL/BADLS) were significantly improved in people treated with ... cognition (ADAS-cog; MMSE), activities of daily living (ADCS-ADL/BADLS), global functioning (CIBIC plus), behavioural and psychological ...
- ... ADAS-Cog= Alzheimer’s Disease Assessment Scale-Cog; ADCS-ADL=Alzheimer’s Disease Cooperative Study-Activities of Daily ... ADAS-Cog= Alzheimer’s Disease Assessment Scale-Cog; ADCS-ADL=Alzheimer’s Disease Cooperative Study-Activities of Daily ...
- ... rivastigmine capsules at 24 weeks, as assessed by ADCS-ADL, but there was a significant benefit for rivastigmine ... living between memantine and placebo, as assessed by ADCS-ADL (MD=0.80, 95%CI −3.22 to ...
51 results